<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275766</url>
  </required_header>
  <id_info>
    <org_study_id>SNCTP610</org_study_id>
    <nct_id>NCT03275766</nct_id>
  </id_info>
  <brief_title>Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders</brief_title>
  <official_title>Effects of Transcranial Magnetic Stimulation on Motor Symptoms of Patients With Psychiatric Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psychomotor slowing may occur in major psychiatric disorders, such as major depressive
      disorders or schizophrenia spectrum disorders. It refers to slowing of fine motor skills,
      motor planning and gross motor behavior. In major depression and schizophrenia, psychomotor
      slowing is associated with alterations of premotor cortex, dorsolateral prefrontal cortex and
      basal ganglia. This randomized, sham-controlled, prospective trial will test, whether 15
      sessions of repetitive transcranial magnetic stimulation (rTMS) may ameliorate psychomotor
      slowing in schizophrenia or major depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psychomotor slowing may occur in major psychiatric disorders, such as major depressive
      disorders or schizophrenia spectrum disorders. It refers to slowing of fine motor skills,
      motor planning and gross motor behavior. In major depression and schizophrenia, psychomotor
      slowing is associated with alterations of premotor cortex, dorsolateral prefrontal cortex and
      basal ganglia. This randomized, sham-controlled, prospective trial will test, whether 15
      sessions of rTMS in 3 weeks may ameliorate psychomotor slowing in schizophrenia or major
      depression.

      Eligible participants will be randomized to one of four arms:
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Salpetriere Retardation Rating Scale total score from baseline to week 3</measure>
    <time_frame>week 3</time_frame>
    <description>observer based rating scale of the severity of psychomotor slowing, assessment blind to intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of responders at week 3</measure>
    <time_frame>week 3</time_frame>
    <description>proportion of participants with &gt; 30% reduction from baseline in the Salpetriere Retardation Rating Scale score at week 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Activity level from baseline to week 3</measure>
    <time_frame>week 3</time_frame>
    <description>actigraphically (wrist of the non-dominant arm) assessed motor activity during the wake periods of one day, given in counts/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in catatonia severity from baseline to week 3</measure>
    <time_frame>week 3</time_frame>
    <description>observer based rating of catatonia severity with the Bush Francis Catatonia Rating Scale, assessment blind to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Fingertapping score from baseline to week 3</measure>
    <time_frame>week 3</time_frame>
    <description>Fingertapping test with the dominant and nondominant index finger for 10 sec, video-taped and blind assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in coin rotation from baseline to week 3</measure>
    <time_frame>week 3</time_frame>
    <description>test of manual dexterity in both hands, rotation of a specified coin for 10 seconds, video-taped and blinded evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in hand gesture performance from baseline to week 3</measure>
    <time_frame>week 3</time_frame>
    <description>videotaped performance of hand gestures according to the Test of Upper Limb Apraxia (TULIA), blind evaluation and rating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in SANS total score from baseline to week 3</measure>
    <time_frame>week 3</time_frame>
    <description>scale for the assessment of negative symptoms, applies to schizophrenia spectrum disorder patients, assessment blind to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from HAMD total score from baseline to week 3</measure>
    <time_frame>week 3</time_frame>
    <description>Hamilton Rating Scale for Depression, 21-item version, applies to depression patients, assessment blind to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in CAINS total score from baseline to week 3</measure>
    <time_frame>week 3</time_frame>
    <description>the clinical assessment interview for negative symptoms, assessment blind to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in PANSS total and subscores from baseline to week 3</measure>
    <time_frame>week 3</time_frame>
    <description>the positive and negative syndrome scale, interview to assess severity of schizophrenia symptoms, applies to schizophrenia spectrum disorder patients, assessment blind to intervention</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Psychomotor Retardation</condition>
  <condition>Psychomotor Slowing</condition>
  <condition>Schizophrenia and Related Disorders</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>DLPFC facilitatory</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC
usually effective in depression treatment, probably no specific effect on psychomotor slowing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>preSMA/SMA inhibitory</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA
should inhibit overactive premotor cortices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>preSMA/SMA facilitatory</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intermittend theta burst stimulation (iTBS) over preSMA/SMA
should facilitate neural activity within premotor cortices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham TMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham rTMS with a placebo coil over occipital cortex
should have no effect at all (no transcranial magnetic stimulation, only sound)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DLPFC facilitatory</intervention_name>
    <description>15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli</description>
    <arm_group_label>DLPFC facilitatory</arm_group_label>
    <other_name>rTMS facilitatory DLPFC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SMA inhibitory</intervention_name>
    <description>1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli</description>
    <arm_group_label>preSMA/SMA inhibitory</arm_group_label>
    <other_name>rTMS inhibitory SMA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SMA facilitatory</intervention_name>
    <description>Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli</description>
    <arm_group_label>preSMA/SMA facilitatory</arm_group_label>
    <other_name>iTBS facilitatory SMA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham TMS</intervention_name>
    <description>Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session</description>
    <arm_group_label>sham TMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suffering from major depressive disorder or schizophrenia spectrum disorder according
             to DSM-5 criteria

          -  right handedness

          -  normal or corrected-to-normal vision and hearing

        Exclusion Criteria:

          -  epilepsy

          -  history of severe head trauma

          -  current abuse of drugs or alcohol; past addiction to drugs or alcohol

          -  pregnancy

          -  incompatibility to cerebral MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Walther, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern, University Hospital of Psychiatry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastian Walther, MD</last_name>
    <phone>+41 31 632 8979</phone>
    <email>sebastian.walther@upd.unibe.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Georgios Schoretsanitis, MD</last_name>
    <phone>+41 31 930 9111</phone>
    <email>georgios.schoretsanitis@upd.unibe.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Psychiatry, University of Bern</name>
      <address>
        <city>Bern</city>
        <zip>3008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgios Schoretsanitis, MD</last_name>
      <phone>+41 31 930 9111</phone>
      <email>georgios.schoretsanitis@upd.unibe.ch</email>
    </contact>
    <contact_backup>
      <last_name>Lea Schäppi, MD</last_name>
      <phone>+41 31 930 9111</phone>
      <email>lea.schaeppi@upd.unibe.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Danai Alexaki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lea Schäppi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgios Schoretsanitis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Walther, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bern</investigator_affiliation>
    <investigator_full_name>Sebastian Walther</investigator_full_name>
    <investigator_title>Prof. Dr., Head of the outpatient clinic, University Hospital of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

